Back to search results

Grape Consumption for Muscle Strength and Cognition in Older Women

This study is looking into whether eating grapes can improve muscle strength and thinking abilities in healthy women aged 65 and older. You would consume two packets of grape powder mixed with water daily for two separate two-week periods. Researchers will measure your muscle strength, thinking abilities (cognition), and take blood samples to see if the grape powder has an effect. The goal is to understand if regular grape intake could be beneficial for older women. This study is currently recruiting 35 participants.

Study design
This interventional study plans to enroll 35 healthy women aged 65 or older. It is not specified if the study is randomized or blinded.
What's involved
You would participate in 4 sessions on campus, which include functional muscle strength testing, cognitive testing, and blood draws. You will consume grape powder daily for two, 2-week periods.
Compensation
Not stated in the trial record.
Follow-up
Blood work, strength, and cognitive testing will be performed on Day 28 and again on Day 42, which is the end of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07208916

Evaluation of the Potential of Grape Consumption to Improve Muscle Strength and Cognitive Function

Recruiting
NAAges 65+InterventionalSupportive care
Western New England University
~35 participants
Updated 2025-10-06 on ClinicalTrials.gov
What's tested:Grape Powder

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Biomarker - Myostatin
Measured over From start of enrollment to the end of treatment at 4 weeks
+9 more outcomes measured

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Brittany C Adams · PRINCIPAL_INVESTIGATOR · Western New England University

Who to contact

Brittany C Adams
[email protected]
413-782-1443
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Healthy female (confirmed by medical history)
Aged 65 or older;
Able to walk household distances without assistance from another person
Non-smoker;
Dominant hand grip strength at or below normal value for age and gender;
Had not consumed recreational drugs for one week prior;
Agreed not to participate in any clinical or patch test studies at Day 1 through study completion;
Completed a medical intake;
Read, understood, and signed an informed consent.

Exclusion

Using nasally inhaled/systemic/topical corticosteroids within 4 weeks prior to and/or during the study, or systemic/topical antihistamines 72 hours prior to and during the study;
Using certain antifungal drugs, antihistamines (including diphenhydramine, or Benadryl), antibiotics 4 (including "sulfa" drugs, quinolones and tetracyclines), oral diabetes drugs, sulfonylureas, diuretics, and tricyclic antidepressants. Some herbal supplements such as St. John's Wort would make a person ineligible;
Not willing to refrain from using acetaminophen (occasional use permitted, except within 48 hours of a study visit) or systemic/topical anti-inflammatory analgesics such as aspirin, Aleve, Motrin, Advil, Orudis, or Nuprin for 72 hours prior to and during study visits;
Any of the following in the 4 weeks prior to start of study:
Known sensitivity or allergy to grape powder;
Nut allergies;
Had received treatment for any type of internal cancer within 5 years prior to study entry;
Had a history of or currently being treated for:
OTHER
Uncontrolled concurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled symptomatic cardiac arrhythmia, psychiatric illness/social situations that limited compliance with study requirements or other underlying serious medical condition which, in the investigator's opinion precluded study participation.

What this trial measures

  • Biomarker - MyostatinFrom start of enrollment to the end of treatment at 4 weeks

    Through serum analysis, myostatin will be measured in units of pg/mL at three points throughout the study.

  • Biomarker - IL-6From start of enrollment through treatment at week 4

    Through serum analysis, Interleukin-6 (IL-6) will be measured in units of pg/mL at three points throughout the study.

  • Biomarker - GDF-15From start of enrollment to the end of treatment at 4 weeks

    Through serum analysis, Growth Differentiation Factor 15 (GDF-15) will be measured in units of pg/mL at three points throughout the study.

  • BIomarker - BDNFFrom start of enrollment through end of treatment at 4 weeks

    Through serum analysis, Brain-derived neurotrophic factor (BDNF) will be measured in units of pg/mL at three points throughout the study.

  • Biomarker - Cystatin CFrom start of enrollment through the end of treatment at 4 weeks

    Through serum analysis, biomarker Cystatin C will be measured in units of pg/mL at three points throughout the study.

  • Biomarker - TNF-αFrom start of enrollment through the end of treatment at 4 weeks

    Through serum analysis, biomarker Tumor necrosis factor-alpha will be measured in units of pg/mL at three points throughout the study.

  • Biomarker - CRPFrom start of enrollment through the end of treatment at 4 weeks

    Through serum analysis, biomarker C-reactive protein (CRP) will be measured in units of pg/mL at three points throughout the study.

  • Biomarker - CCL-2/MCP-1From start of enrollment through the end of treatment at 4 weeks

    Through serum analysis, biomarker C-C motif chemokine ligand 2 / Monocyte chemoattractant protein 1 will be measured in units of pg/mL at three points throughout the study.

  • Biomarker - CAFFrom start of enrollment through the end of treatment at 4 weeks

    Through serum analysis, biomarker C-terminal fragment of agrin (CAF) will be measured in units of pg/mL at three points throughout the study.

  • Biomarker - MalondialdehydeFrom start of enrollment through the end of treatment at 4 weeks

    Through serum analysis, biomarker malondialdehyde will be measured in units of µM at three points throughout the study.